Amgen Inc. - The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation.

The Group's key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis.

Thousand Oaks, US

Key People at Amgen

Suzanne Blaug

Suzanne Blaug

SVP, Global Marketing and Commercial Development
Christopher Barr

Christopher Barr

Senior Manager Research Operations
Stuart A. Tross

Stuart A. Tross

SVP of Human Resources
Robert A. Bradway

Robert A. Bradway

Chairman and Chief Executive Officer
Anthony C. Hooper

Anthony C. Hooper

EVP, Global Commercial Operations
Madhavan Balachandran

Madhavan Balachandran

EVP, Operations

Amgen Locations

Thousand Oaks, US
South San Francisco, US
Dublin, IE
Breda, NL
Prague, CZ
Stockholm, SE
Brussels, BE
Asheville, US
Budapest, HU
Tallahassee, US
Washington, US
Cambridge, US
Riyadh, SA
Honolulu, US
Columbus, US
Paris, FR
Cairo, EG
San Francisco, US

Amgen Metrics

Amgen Summary

Founding Date


Market capitalization

$118 B

Closing share price


Amgen Market Value History

Amgen News

Amgen Company Life